Takeda’s Hikari Manufacturing Site Marks 80th Anniversary | Takeda Pharmaceuticals
Takeda’s Hikari Manufacturing Site Marks 80th Anniversary
Evolving from a postwar vaccine manufacturing facility into a global manufacturing site supplying medicines to patients in Japan and around the world
OSAKA, Japan, November 16, 2026 – Takeda (TSE:4502/NYSE:TAK) commemorated the 80th anniversary of its Hikari Site in Yamaguchi Prefecture with a ceremony on November 13. Established in May 1946, Hikari Site is marking 80 years of manufacturing in 2026. Beginning with vaccine production in postwar Japan, Hikari Site has expanded its role over the decades and evolved into a global manufacturing site with advanced pharmaceutical manufacturing capabilities, technologies and highly skilled people, supplying medicines to patients in Japan and around the world. As the site marks this important milestone, Takeda will continue to strengthen its manufacturing capabilities, advance its technologies and develop its people, carrying this expertise forward to future generations while maintaining a reliable supply of high-quality medicines to patients and others who depend on them.
Eight Decades of Manufacturing
Hikari Site was established in May 1946 on the former site of a Japanese naval arsenal. Against the backdrop of the serious public health challenges facing Japan after World War II, the site began manufacturing vaccines in response to urgent societal needs. Over the decades, the site expanded its production portfolio in response to evolving healthcare needs, including antibiotics, vitamins and treatments for chronic diseases.
Supporting Reliable Supply from Japan to the World Through Advanced Manufacturing
Today, Hikari Site manufactures a broad range of medicines requiring advanced technical expertise, from active pharmaceutical ingredients and solid-dose medicines to sterile products and biologics, including products involving highly potent compounds. Its technical capabilities have also received external recognition. In 2021, the site’s solid-dose packaging facility received the International Society for Pharmaceutical Engineering’s Facility of the Year Award in the Process Intelligence and Innovation category. Hikari Site continues to build on its manufacturing expertise, using data and digital technologies to further enhance quality and supply reliability.
One example is the collaboration between manufacturing and data science experts. On a production line for injectable medicines used to treat conditions including cancer, teams analyze manufacturing data to improve yield, helping the site make better use of available materials and supply medicines to more patients.
In 2024, Takeda invested approximately JPY 7 billion in a new manufacturing line for a biologic medicine in the gastrointestinal and inflammation therapeutic area, which is supplied to approximately 80 countries and regions, including Japan. The investment increased the site’s manufacturing capacity for the medicine by approximately threefold. The new line incorporates technologies including isolators and real-time manufacturing monitoring to maintain high standards of sterility and quality. Augmented reality (AR) and virtual reality (VR) are also used in training for the new line to help develop the highly specialized expertise required for advanced pharmaceutical manufacturing.
Hikari Site’s role has expanded to include delivering new treatment options, including an innovative medicine in the neuroscience therapeutic area supplied to the Japanese market. The site also continues to manufacture medicines it has supplied to patients over many years. Through this broad portfolio, Hikari Site supports patients with both established and new treatment options.
Hideki Fujiwara, Site Head, Hikari, Takeda, said, “Every medicine we manufacture matters to patients and people who depend on it. Hikari Site’s 80-year history reflects the unwavering commitment of generations of employees to quality and to the people our medicines serve. We are deeply grateful to the local community, our partners, and the generations of employees who have carried this mission forward. We will continue to build on this legacy as we look toward the next 80 years.”
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit https://www.takeda.com.
Important Notice
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this press release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
The product names appearing in this document are trademarks or registered trademarks owned by Takeda, or their respective owners.
Forward-Looking Statements
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects”, “forecasts”, “outlook” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including drug pricing, tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic; the success of our environmental sustainability efforts, in enabling us to reduce our greenhouse gas emissions or meet our other environmental goals; the extent to which our efforts to increase efficiency, productivity or cost-savings, such as the integration of digital technologies, including artificial intelligence, in our business or other initiatives to restructure our operations will lead to the expected benefits; and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.
Contact:
Kumi Iiyama
[email protected]